RNS Number : 1039U

OptiBiotix Health PLC

01 December 2021

OptiBiotix Health plc

("OptiBiotix" or the "Company")

Launch of LeanBiome (TM) with global leader in beauty & nutrition brands

OptiBiotix Health plc (AIM: OPTI), announces the launch of a new sports nutrition product range branded LeanBiome (TM) alongside a new supply & licensing agreement with a leading global player in beauty & nutrition ("the Partner"). This agreement grants the Partner a license to manufacture and sell finished products containing LeanBiome (TM) across Europe, Australia and Asia.

OptiBiotix is a life sciences business developing patented science and human study-based compounds that modulate the microbiome to address metabolic syndrome and diabetes, systemic low-grade inflammation, obesity, cardiovascular disease, high cholesterol and supports healthy aging.

The Partner is a British e-commerce company which specialises in taking beauty and nutrition brands direct to consumer ("D2C") through its proprietary e-commerce platform across the globe. The Partner's technology, brand building expertise, and global infrastructure allows it to reach millions of customers around the world. They own the largest D2C sports nutrition brand globally.

LeanBiome (TM) is a scientifically formulated sports nutrition ingredient which has been developed by OptiBiotix that supports athletes seeking to increase lean muscle mass to change their body composition. LeanBiome(TM) contains a patented combination of fibres, prebiotics and minerals aimed specifically at supporting the microbiome diversity of athletes on a high protein diet. LeanBiome(TM) adds unique differentiation to a new premium product line of the Partner and will get on-pack recognition. The new product line of the Partner is aimed at increasing lean muscle mass which is scheduled to be rolled out from January 2022 in Europe and Asia. If the product line is successful, it is expected to be introduced to the North American market in due course. The agreement is expected to generate approximately GBP1m in annualised and recurring turnover for the Company starting in 2022. First orders worth GBP200k have been placed and are on schedule for delivery in early December 2021.

There is growing scientific evidence of an anecdotal link between the microbiome and athletic performance ( Do microbes affect athletic performance? (nature.com) .

This agreement is part of OptiBiotix's strategy to offer pro- and prebiotic solutions aimed at modulating the microbiome that allow leading brands to differentiate their health & wellness products.

René Kamminga, C EO of O pti B i oti x Limited, c o mmented : "We are very pleased to announce this agreement with the Partner and its sports nutrition division. LeanBiome(TM) has been specifically formulated with the needs of athletes in mind and builds on our core expertise in functional ingredients with effect on the microbiome to achieve health effects. The Partner is a formidable company to partner with and we are pleased that LeanBiome -- has been selected as the preferred source of differentiation for their new product line. This launch is another important step in building sales and brand presence for OptiBiotix' solutions with major partners around the world."

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

For further information, please contact:

 OptiBiotix Health plc                               www.optibiotix.com 
 Stephen O'Hara, Chief Executive                   Contact via Walbrook 
 Cairn Financial Advisers LLP (NOMAD)                Tel: 020 7213 0880 
 Liam Murray / Jo Turner / Ludovico Lazzaretti 
 Cenkos Securities plc (Broker)                      Tel: 020 7397 8900 
 Callum Davidson / Neil McDonald 
 Michael Johnson / Russell Kerr (Sales) 
 Walbrook PR Ltd                                     Mob: 07876 741 001 
 Anna Dunphy 

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identiÞed by their use of terms and phrases such as "believe", "could", "should" "envisage", "estimate", "intend", "may", "plan", "potentially", "expect", "will" or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reßect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

December 01, 2021 01:59 ET (06:59 GMT)

Grafico Azioni Optibiotix Health (LSE:OPTI)
Da Lug 2022 a Ago 2022 Clicca qui per i Grafici di Optibiotix Health
Grafico Azioni Optibiotix Health (LSE:OPTI)
Da Ago 2021 a Ago 2022 Clicca qui per i Grafici di Optibiotix Health